Circle Pharma is a clinical-stage biopharmaceutical company developing targeted macrocycle therapeutics for cancer. Its proprietary platform designs macrocyclic small molecules against previously undruggable targets, with lead candidate CID-165, an oral cyclin D1 inhibitor for ER-positive breast cancer.